Out of control—or delivering value?
Is affordability a pipe dream?
Complexities in forecasting eligible cases and associated costs of cell and gene therapy
Read the articleRelated insight
From ASP to WAC: 8 key drug pricing terms life science companies should know
We review some commonly used drug-pricing terms in the U.S. pharmaceutical market, including their calculations and roles in the healthcare industry.
4 key takeaways from the third round of drugs selected for Medicare drug price negotiation
The Centers for Medicare and Medicaid Services announced the list of drugs selected for price negotiation for 2028. We broke down the implications.
Medicare drug price negotiation: New dynamics as the tide turns to Medicare Part B
Medicare drug price negotiation: With the first cycle where Part B drugs are eligible to be selected, the implications extend far beyond simple price reductions.
6 issues Milliman is watching for Medicare Advantage plans in 2026
To help Medicare Advantage plans navigate significant challenges and opportunities in 2026, we offer insight on six developing issues.
6 key takeaways from the 2026 MA and prescription drug bids for life sciences companies
We discuss key insights from the 2026 Medicare Advantage bids that life sciences leaders should consider when planning for the future.
Beyond FDA approval: 5 factors in clinical trial design that influence health insurance coverage decisions
We detail factors in Phase-3 clinical trial design that influence health insurance coverage decisions.
The impact of medication adherence on total healthcare costs for commercially insured patients
A current perspective for patients with diabetes, hypertension, and hyperlipidemia
Emerging Medicare Advantage and Part D trends from 2024 financial statements
Medicare Advantage (MA) and Part D insurers are citing significant financial headwinds in earnings calls and the press. Statutory financial statements provide insights into emerging trends through year-end 2024.
Medicare price negotiation: Anchored drug prices in uncharted waters
Maximum Fair Price (MFP) Issue Brief 2
The evolution of biosimilars in the United States
Biosimilars recently have made significant strides toward greater acceptance and utilization since their first U.S. approval in 2015, although challenges persist.
Related Milliman products
MyRxConsultant
Healthcare Reform Dashboard
